Table 1.
Demographic and clinicopathological characteristics of enrolled patients.
| Overall | Discovery phase | Validation phase | ||||
|---|---|---|---|---|---|---|
| De novo | Progressive | De novo | Progressive | De novo | Progressive | |
| MIBC | MIBC | MIBC | MIBC | MIBC | MIBC | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Overall | 108 | 104 | 12 | 14 | 96 | 90 |
| Gender | ||||||
| Male | 90 (83.3) | 69 (66.3) | 12 (100) | 13 (92.9) | 78 (81.2) | 56 (62.2) |
| Female | 18 (16.7) | 35 (33.7) | – | 1 (7.1) | 18 (18.8) | 34 (37.8) |
| Median age (years) | 69 | 72 | 66 | 74 | 72 | 71 |
| Pathological stage | ||||||
| pT0–T1 | 28 (26) | 11 (10.6) | 8 (66.6) | 1 (7.1) | 20 (20.8) | 10 (11.1) |
| pT2 | 50 (46.3) | 46 (44.2) | – | 9 (64.3) | 50 (52.1) | 38 (42.2) |
| pT3 | 20 (18.5) | 29 (27.9) | 2 (16.7) | 3 (21.5) | 18 (18.8) | 26 (28.9) |
| pT4 | 10 (9.2) | 18 (17.3) | 2 (16.7) | 1 (7.1) | 8 (8.3) | 16 (17.8) |
| Carcinoma in situ (CIS) | 36 (33.3) | 20 (19.2) | 7 (58.3) | 3 (21.5) | 29 (30.2) | 17 (18.9) |
| Lymph nodes (LN) | ||||||
| LN(+) | 20 (18.5) | 30 (28.8) | 3 (25) | – | 17 (17.7) | 30 (33.3) |
| LN(−) | 88 (81.5) | 74 (71.2) | 9 (75) | 14 (100) | 79 (82.3) | 60 (66.7) |
| Neoadjuvant Chemotherapy | 29 (26.8) | 6 (5.6) | 10 (83.3) | – | 19 (19.8) | 6 (6.7) |
| Median TURBT Number | – | 3 | – | 3 | – | 2.5 |
| Last NMIBC stagea | – | |||||
| T0 | – | 7 (6.7) | – | 2 (14.3) | – | 5 (5.6) |
| Ta | – | 23 (22.1) | – | 3 (21.5) | – | 20 (22.2) |
| T1 | – | 49 (47.1) | – | 8 (57.1) | – | 41 (45.6) |
| CIS | – | 11 (10.6) | – | 1 (7.1) | – | 10 (11.1) |
aLast NMIBC stage was not available in 14 progressive patients.